TREATING CHILDREN TO PREVENT EXACERBATIONS OF ASTHMA (TREXA)

治疗儿童预防哮喘恶化 (TREXA)

• 批准号: 7603413
• 负责人: Robert Strunk
• 金额: $ 0.11万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603413
• 关键词: Address; Adrenal Cortex Hormones; Albuterol; Asthma; Breathing; Child; Computer Retrieval of Information on Scientific Projects Database; Daily; Disease; Dose; Funding; Grant; Guidelines; Institution; Knowledge; Patients; Pharmaceutical Preparations; Placebos; Process; Research; Research Personnel; Resources; Source; Symptoms; Testing; Time; United States National Institutes of Health; Weaning; Week; base; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. With inhaled corticosteroid (ICS) established as the best medication for mild persistent asthma, a crucial unresolved issue in children whose asthma is under good control with daily ICS is for how long this treatment has to be maintained and when is it safe to wean and/or discontinued daily therapy. To our knowledge, no studies have systematically addressed this issue, or defined the criteria on which to base this decision. The NAEPP guidelines suggest that, in this group of patients, reducing ICS therapy can be considered after a 1-3 month period of acceptable control of symptoms; however, given the paucity of evidence, the Guidelines offer no parameters that would guide the clinician in this process. Another important consideration is treatment of exacerbations that occur intermittently in children with otherwise mild disease when a child has stopped regular medications. TReating children to prevent EXacerbations of Asthma will test the hypothesis that children with mild persistent asthma, under good control on low dose ICS and thus eligible for weaning from ICS, do not differ in their effects on time to first asthma exacerbation during 44 weeks of therapy with: 1. the same dose of ICS twice daily and use of ICS + albuterol as reliever; 2. the same dose of ICS twice daily and use of placebo ICS + albuterol as reliever; 3. placebo ICS twice daily and use of ICS + albuterol as reliever; 4. placebo ICS twice daily and use of placebo ICS + albuterol as reliever

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 将吸入的皮质类固醇（ICS）确立为轻度持续性哮喘的最佳药物，在每日ICS良好控制哮喘的儿童中，至关重要的尚未解决的问题是必须维持这种治疗方法，并且何时安全地对WEAN和/或每日治疗安全。 据我们所知，没有任何研究系统地解决了这个问题，或者定义了该决定的标准。 NAEPP指南表明，在这组患者中，可以在1-3个月的可接受控制症状后的1-3个月后考虑减少ICS疗法。但是，鉴于证据很少，该准则不提供任何参数可以指导临床医生在此过程中。 另一个重要的考虑因素是治疗患有常规药物的儿童时，会间歇性地发生的恶化。 治疗儿童以防止哮喘的恶化，将检验以下假设：在低剂量IC的良好控制下，有轻度持续性哮喘的儿童在低剂量的情况下良好控制，因此有资格从ICS中断奶，在44周在治疗期间对： 1。每天两次同样的ICS剂量，并使用ICS + Albuterol作为缓解剂； 2。每天两次相同的ICS剂量，并使用安慰剂ICS + Albuterol作为缓解剂； 3.安慰剂ICS每天两次，并使用ICS + Albuterol作为缓解剂； 4.安慰剂ICS每天两次，使用安慰剂ICS + Albuterol作为救济者